Health Care • Industrial Specialties
$92.01 ▼ -2.43
(-2.57%)
MKT CAP: $54.44B • VOL: 6.04M
52W L $75 52W H $96
EW // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.07B | $5.44B | $5.01B |
| YoY Revenue Growth % | +11.5% | +8.6% | — |
| Gross Profit | $4.73B | $4.32B | — |
| Gross Margin % | 78.0% | 79.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.26B | $1.38B | $1.31B |
| Operating Margin % | 20.8% | 25.3% | 26.1% |
| Net Income (GAAP) | $1.07B | $4.17B | $1.40B |
| EBITDA (Normalized) | $1.47B | $1.58B | $1.49B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.60B | $542.3M | $895.8M |
| Capital Expenditures (CapEx) | $260.2M | $252.4M | $225.4M |
| Free Cash Flow (FCF) | $1.33B | $289.9M | $670.4M |
| FCF Margin % | 22.0% | 5.3% | 13.4% |
| Return on Invested Capital (ROIC %) | 12.5% | 14.4% | 5.7% |
| Cash & Short-Term Equivalents | $2.94B | $3.05B | — |
| Total Debt (Short + Long Term) | $598.3M | $597.7M | $7.01B |
| Total Stockholders' Equity | $10.34B | $10.00B | $14.37B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EW.